Biofrontera Inc. [BFRI] fell -34.04% so far this year. What now?

Related

Share

Biofrontera Inc. [NASDAQ: BFRI] jumped around 1.26 points on Wednesday, while shares priced at $4.96 at the close of the session, up 34.05%. The company report on April 13, 2022 that Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Significantly Improves Manufacturing Efficiency, Quality Control and Supply Reliability.

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the U.S. Food and Drug Administration (FDA) has approved Biofrontera Pharma’s cGMP laboratory in Leverkusen, Germany, as a contract laboratory for batch control and stability testing of Ameluz® (aminolevulinic acid hydrochloride gel, 10%). This recognition enables significant improvements in product manufacturing efficiency, quality control and reliability of supply.

Compared to the average trading volume of 2.40M shares, BFRI reached a trading volume of 32021683 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Biofrontera Inc. [BFRI]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BFRI shares is $15.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BFRI stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for Biofrontera Inc. is set at 0.65, with the Price to Sales ratio for BFRI stock in the period of the last 12 months amounting to 2.14.

How has BFRI stock performed recently?

Biofrontera Inc. [BFRI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 40.11.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BFRI stock in for the last two-week period is set at 67.30, with the RSI for the last a single of trading hit 70.64, and the three-weeks RSI is set at 62.56 for Biofrontera Inc. [BFRI]. The present Moving Average for the last 50 days of trading for this stock 3.27, while it was recorded at 4.30 for the last single week of trading.

Biofrontera Inc. [BFRI]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Biofrontera Inc. [BFRI] shares currently have an operating margin of -44.21 and a Gross Margin at +48.92. Biofrontera Inc.’s Net Margin is presently recorded at -58.29.

Return on Total Capital for BFRI is now -120.36, given the latest momentum, and Return on Invested Capital for the company is -158.67.

Receivables Turnover for the company is 4.67 with a Total Asset Turnover recorded at a value of 0.71.Biofrontera Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.40 and a Current Ratio set at 0.90.

Insider trade positions for Biofrontera Inc. [BFRI]

There are presently around $3 million, or 6.00% of BFRI stock, in the hands of institutional investors. The top three institutional holders of BFRI stocks are: BARD ASSOCIATES INC with ownership of 343,025, which is approximately New of the company’s market cap and around 69.00% of the total institutional ownership; VANGUARD GROUP INC, holding 153,273 shares of the stock with an approximate value of $0.76 million in BFRI stocks shares; and VERITION FUND MANAGEMENT LLC, currently with $0.28 million in BFRI stock with ownership of nearly New of the company’s market capitalization.

Positions in Biofrontera Inc. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 14 institutional holders increased their position in Biofrontera Inc. [NASDAQ:BFRI] by around 700,507 shares. Additionally, 0 investors decreased positions by around 0 shares, while 0 investors held positions by with 0 shares. The mentioned changes placed institutional holdings at 700,507 shares, according to the latest SEC report filing. BFRI stock had 14 new institutional investments in for a total of 700,507 shares, while 0 institutional investors sold positions of 0 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]